Zoetis to Sell Medicated Feed Additive Portfolio to Phibro Animal Health
Zoetis Inc. (NYSE:ZTS) and Phibro Animal Health Corporation(Nasdaq: PAHC) today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024.
Phibro Animal Health Corporation Announces Chief Financial Officer Changes
Phibro Animal Health Corporation today announced that Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024. Mr. Richard Johnson, who is currently serving as Phibro’s interim Chief Financial Officer since September 29, 2023, will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with his successor.
Vetoquinol Defies Market Trends: How This Animal Health Giant Outperformed in a Flat 2023 Market
Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), has announced a remarkable performance in a challenging 2023 animal health market, attributing the company's resilience and agility to its success. Despite flat market volumes, Vetoquinol's 2023 sales were buoyed by the strong showing of their Essentials product line in the latter half of the year, demonstrating sustained growth and operational efficiency